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Abstract
κ opioid receptor activation by traditional arylacetamide agonists and the novel neoclerodane
diterpene κ opioid receptor agonist Salvinorin A (Sal A) results in attenuation of cocaine-seeking
behavior in pre-clinical models of addiction. However, adverse effects such as sedation,
depression and aversion limit their clinical utility. The Sal A analogue, 2-methoxymethyl
salvinorin B (MOM Sal B) is a longer acting Sal A analogue with high affinity for κ opioid
receptors. In this study, we tested MOM Sal B for its ability to modulate cocaine-seeking behavior
in rats. MOM Sal B (0.3 mg/kg) successfully attenuated cocaine-seeking but also attenuated
sucrose reinforcement. No change in activity was observed in either cocaine-induced hyperactivity
or spontaneous open field activity tests but increased immobility and decreased swimming times
in the forced swim test were observed. This study indicates that κ opioid receptor activation by
more potent Sal A analogues modulates cocaine-seeking behavior non-selectively without causing
sedation, suggesting an improved side effects profile. However, pro-depressive effects are seen,
which may limit the therapeutic potential of this compound. Future studies with Sal A analogues
having affinities at other opioid receptors are warranted as they have the potential to identify
compounds having effective anti-addiction properties.
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1. Introduction
Attenuation of drug self-administration by acute κ opioid receptor activation has been
shown in rodents (Glick et al., 1995) and non-human primates (Mello and Negus, 1998).
Behavioral effects of cocaine (Heidbreder et al., 1993, 1995), amphetamine (Gray et al.,
1999), and nicotine (Hahn et al., 2000) have also been antagonized by pre-treatment with κ
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opioid receptor agonists. These findings have prompted further studies into the potential
development of these compounds as anti-addiction pharmacotherapies (Prisinzano et al.,
2005; Shippenberg et al., 2001, 2007), particularly in the binge or intoxication phase where
κ opioid agonists antagonise the rewarding effects of drugs of abuse, for recent reviews see
(Butelman et al 2012; Shippenberg 2009, Wee and Koob 2010). However, adverse side
effects including sedation (Butelman et al., 2007, 2009), dysphoria (Pfeiffer et al., 1986;
Walsh et al., 2001) and depression (Todtenkopf et al., 2004) have limited the clinical
development of traditional acrylacetamide κ opioid agonists. Antagonists of κ opioid
receptors have been suggested to have therapeutic use later in the addiction cycle as they
have been shown to modulate stress pathways in addiction (Chavkin 2011).
Sal A, a neoclerodane diterpene derived from Salvia divinorum, was shown to selectively
bind with high affinity to κ opioid receptors (Roth et al., 2002). Therefore, Sal A, a non-
nitrogenous κ opioid receptor agonist has characterized a novel class of κ opioid receptor
ligand. Sal A binds to κ opioid receptors with greater potency than U69593 or U50488H
(Chavkin et al., 2004) and is 40-fold less potent than U50488H in its ability to internalize κ
opioid receptors (Wang et al., 2005). These findings suggest that although it is a potent κ
opioid receptor agonist, Sal A might differ pharmacologically and behaviorally from
traditional arylacetamide κ opioid receptor agonists (Beguin et al., 2012; Fantegrossi et al.,
2005; Prisinzano, 2005).
In vivo studies with Sal A have shown that it has a rapid onset of action (approx 5 min) and
an elimination half-life of approximately 50 min (Butelman et al. 2009; Hooker et al., 2008;
Schmidt et al., 2005). The short duration of action is thought to be due to its rapid
metabolism at position C-2 to a pharmacologically inactive metabolite, salvinorin B (Beguin
et al., 2005; Chavkin et al., 2004). However, other mechanisms are likely involved as well
(Butelman et al., 2012). Structure activity relationships have revealed the importance of the
C-2 acetoxy group for binding to and activation of κ opioid receptors (Beguin et al., 2008;
Prisinzano and Rothman, 2008; Prevatt-Smith et al., 2011). Sal A analogues with C-2
substitution such as MOM Sal B have been shown to have a longer half-life in vivo (Baker et
al., 2009; Wang et al., 2008). In vitro studies indicate that it is five- and seven-fold more
potent at κ opioid receptors than U50488H and Sal A, respectively (Wang et al., 2008).
Behavioral pharmacology studies with MOM Sal B have shown antinociception, motor
suppression, hypothermia and diuresis (Inan et al., 2009; Wang et al., 2008). Recent reports
show that MOM Sal B completely substituted for U50488H and Sal A in discriminative
stimulus tests in rats (Peet and Baker, 2011). Work has been reported with Sal A analogues
characterizing their anti-addiction profiles (Chartoff et al., 2008; Morani et al., 2009, 2012).
Therefore, we tested the effect of MOM Sal B on cocaine-seeking using a cocaine prime
induced reinstatement paradigm in rats (Dewit and Stewart, 1981, 1983). We also tested the
effect of MOM Sal B on motor function (spontaneous locomotion and cocaine induced
hyperactivity), reward reinforcement (sucrose reinforcement) and depression (forced swim
test, FST).
2. Materials and Methods
2.1. Subjects
Male Sprague-Dawley rats weighing 325-350 g (for cocaine self-administration), 250-300 g
(for sucrose reinforcement and spontaneous locomotion tests) and 350-400 g (for forced
swim test) were used. Self-administering rats were housed individually in hanging
polycarbonate cages in a temperature and humidity (55% relative humidity, 19-21°C)
controlled room. Rats used for sucrose reinforcement, spontaneous locomotion and forced
swim tests were housed in groups of 2-3 per cage. The lights were maintained on a 12/12 h
cycle with lights on at 0700 h. Animals used for reinstatement tests, locomotion experiments
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and forced swim tests had free access to food and water except during testing. Animals
tested for sucrose reinforcements had free access to water within their home cages and were
maintained at approximately 85% of their initial feeding weights during the experiments by
restricting access to food. The animal colonies were maintained at the School of Psychology,
Victoria University of Wellington. All experimental procedures were reviewed and
approved by the Animal Ethics Committee of Victoria University of Wellington, New
Zealand.
2.2. Surgery
Under deep anesthesia produced by ketamine/xylacine (90/9 mg/kg, intraperitoneal, i.p.), the
right external jugular vein was isolated and a silastic catheter was inserted. The distal end
(22 gauge stainless steel tubing) was passed subcutaneously (s.c.) to an exposed portion of
the skull where it was fixed to embedded jeweler’s screws with dental acrylic. Rats received
carprofen (5 mg/kg, s.c.) at 0, 24, and 48 h post-surgery. In order to prevent infection and
clot formation, the catheters were daily infused with 0.1 ml of a sterile saline solution
containing heparin (30.0 U/ml), penicillin G Potassium (250,000 U/ml) and streptokinase
(8000 U/ml). Testing began five days post-surgery.
2.3. Apparatus
2.3.1. Cocaine Self administration—Self-administration training and reinstatement
tests were carried out in humidity (55% relative humidity) and temperature (19-21°C)
controlled rooms containing standard operant chambers equipped with two levers (Med
Associates, ENV-001, VT, USA). Depression of the active lever led to a programmed
intravenous (i.v.) infusion of a 0.l ml solution of cocaine hydrochloride dissolved in sterile
physiological saline containing heparin (3.0 U/ml) in order to maintain the patency of the
catheter. The infusions were of 12 s duration and were accompanied by the illumination of a
stimulus light located directly above the active lever. This stimulus light remained
illuminated throughout each 12 s cocaine infusion. Depression of the other lever (the
inactive lever) was without programmed consequence. Prior to each training and testing
session, the catheter lines were infused with 0.1 ml of the heparin-penicillin-streptokinase
solution. The stainless steel catheter was connected to the syringe by a length of microbore
tubing. After completion of each session, the lines were again infused with 0.1 ml of the
heparin-penicillin-streptokinase solution, the stainless steel tubing was plugged, and the
animal was returned to its home cage. Drug delivery and data acquisition were controlled by
Med Associates software. Cocaine deliveries were made via mechanical pumps (Razel
Scientific, Model A with 1.0 rpm motor equipped with 20 ml syringe; VT, USA).
2.3.2. Sucrose self-administration apparatus—Eight standard operant chambers
(Med Associates, ENV-008) placed in a light and sound attenuating room were used for
training and testing. Each operant chamber had two retractable levers with a bottle
delivering 0.1 ml of 10% sucrose solution in a tray placed on the chamber wall. The sucrose
was delivered according to the imposed schedule of reinforcement. Sucrose delivery and
data acquisition were controlled by Med Associates software. All experiments were
conducted between 0900 and 1600 h.
2.3.3. Locomotion activity tests—Eight Open field chambers (Med Associates
ENV-520) were used for this test. Each chamber was equipped with two banks of 16
photocells on each wall to measure horizontal and vertical locomotion. The open field boxes
were interfaced with a microcomputer located in an adjacent laboratory. Testing was
conducted in the dark between 1000 and 1600 h. White noise was present throughout the
experiment.
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2.3.4. Forced swim tests (FST)—The FST chamber was a cylindrical chamber of 44 cm
in height and a diameter of 20 cm with water level up to a depth of 30 cm. Water
temperatures was maintained at 25+1°C.
2.4. Procedure
2.4.1. Cocaine self-administration training and reinstatement test—Rats were
trained to self-administer cocaine during daily 2 h sessions. During each session the animals
received an experimenter-delivered infusion of cocaine (0.5 mg/kg/infusion (cocaine
hydrochloride dissolved in sterile physiological saline containing heparin (3.0 U/ml)).
Thereafter, depression of the active lever produced automated cocaine infusions. Initially the
animals were maintained on FR-1 schedule of reinforcement (single infusion following a
single lever press). The criterion for acquisition of cocaine self-administration consisted of
three consecutive days during which there were at least 20 reinforced responses (10 mg/kg
during a single session) and a ratio of active: inactive lever responses of at least 2:1.
Following acquisition, the reinforcement schedule was increased to FR-5 (five lever presses
resulted in a single infusion). Daily 2 h sessions were conducted until there was less than
20% variation in responding for three consecutive days. Once responding under the FR-5
schedule was stable, the effect of MOM Sal B pre-treatment on drug seeking was measured.
The procedures followed for this test have been described previously (Morani et al., 2009;
Schenk et al., 1999, 2001; Schenk and Partridge, 2001). Briefly, testing was conducted on a
single day and consisted of three phases. During the first phase the animals were allowed to
self-administer cocaine (0.5 mg/kg/infusion, FR-5 schedule of reinforcement) for 1 h. This
was followed by a 3 h phase in which the cocaine solution was replaced by heparinized
saline (FR-5 schedule of reinforcement). At the beginning of the third phase the number of
responses were recorded for saline reinforcement (FR-5 schedule of reinforcement) for 1 h.
Prior to the commencement of this phase, separate groups of rats (n = 5-6 per group)
received an injection of either vehicle (75% DMSO, 1 ml/kg, i.p.) or MOM Sal B (0.03, 0.1
or 0.3 mg/kg, i.p.). All treatments were administered using the Latin square design. Five min
following vehicle / MOM Sal B injections, animals received a priming injection of cocaine
(20 mg/kg, i.p. in sterile physiological saline) and active lever responses measured for 60
min. The 5 min pre-treatment time was chosen based on previously published reports on
MOM Sal B indicating a rapid onset of action (Baker et al., 2009; Wang et al., 2008).
2.4.2. Oral sucrose self-administration training and reinforcement—Drug naïve
rats were trained to orally self-administer 10% sucrose solution using a daily 45 min auto-
shaping procedure. This procedure was repeated for 10 days. Once responding for sucrose
was stable, animals were trained on FR-1 schedule of reinforcement, during which pressing
the active lever delivered 0.1 ml of a 10% sucrose solution. Once responding on this
schedule was stable, the response requirements were increased to FR-5 (five lever press to
receive one infusion). Daily 1 h sessions were conducted until there was less than 20%
variation in responding for three consecutive days. Once responding on the FR-5 schedule
was stable, the effect of MOM Sal B on sucrose-reinforced responding was measured. Rats
were treated with either MOM Sal B (0.3 mg/kg, i.p.) or vehicle (75% DMSO) 5 min prior
to sucrose self-administration, and the number of responses recorded for 60 min.
2.4.3. Cocaine induced hyperactivity (drug naive and cocaine self
administering rats)—On the test day, separate groups of rats (n = 5-6 per group),
following a 30 min habituation phase, were injected with either MOM Sal B (0.3 mg/kg,
i.p.) or vehicle (75% DMSO, 1 ml/kg, i.p.), 5 min prior to an injection of cocaine (20 mg/kg,
i.p.). The rats were immediately placed in the activity chambers and total activity, a
compilation of horizontal and vertical activity, were measured for a period of 60 min.
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2.4.4. Spontaneous open field activity—On the test day, following a 30 min
habituation phase, drug naïve rats were injected with either vehicle (75% DMSO, i.p.) or
MOM Sal B (0.3 mg/kg, i.p.) and 5 min later ambulation counts were measured at 5 min
intervals for 60 min.
2.4.5. Forced swim tests (FST)—Drug-naïve rats were tested using the modified FST
method as described in Slattery and Cryan (2012). This method is a modified version of the
original FST designed by Porsolt (1979). On day 1, drug-naïve rats were habituated to
swimming conditions in the FST chamber for 15 min. The following day, rats were injected
with either vehicle (75% DMSO, i.p.) or MOM Sal B (0.3 mg/kg, i.p.) 5 min before being
placed into the swim chamber for 5 min. Behavior was recorded using a camera and scored
in 5 sec intervals by an observer who was blinded to experimental procedures.
2.5. Drugs
Cocaine HCl (Merck KGaA, Darmstadt, Germany) was dissolved in physiological saline
containing heparin (3.0 U/ml) for all i.v. infusions and in physiological saline for i.p.
injections. MOM Sal B (synthesized by Professor Thomas E. Prisinzano, University of
Kansas) was suspended in 75% DMSO. Infusions (i.v.) were in a volume of 100 μl and i.p.
injections were administered in a volume of 1 ml/kg. All drug weights refer to the salt.
2.6. Statistical analysis
Statistical tests were performed using Prism GraphPad 5 software (San Diego, CA). Data for
the drug-seeking tests were analyzed using one way ANOVA followed by Tukey post-hoc
comparisons. Results for sucrose reinforcements, total activity for cocaine induced
hyperactivity and forced swim tests were analyzed using student t-tests. Data for cocaine
induced hyperactivity and spontaneous open field activity at 5 min intervals were analyzed
using repeated measures two way ANOVA followed by Bonferroni post hoc tests. One-way
repeated measures ANOVA was performed between phases 1 and 2 of the self-
administration test.
3. Results
3.1. Phase 1 and 2 of the reinstatement test
Figure 1 shows the number of active lever responses during phase 1 and phase 2 of the
reinstatement test. Active lever responding during the 60 min time period comprising phase
1 was high (102.9 ± 10.3). During phase 2, cocaine solution was replaced with saline and the
active lever responses decreased (11.3 ± 2.9) (*** P<0.001; **** P<0.0001).
3.2. Effect of MOM Sal B on cocaine-prime induced reinstatement
Figure 2 shows the number of lever responses during phase 3. A priming injection of
cocaine reinstated extinguished cocaine self-administration behavior; and this behavior was
attenuated by pre-treatment with MOM Sal B [0.3 mg/kg, F (3, 17) = 4.71, P<0.05; Fig. 2].
A non-significant trend towards an increase in the active lever responses following pre-
treatment with the low doses (0.03, 0.1 mg/kg) of MOM Sal B was also observed (P=0.2
between 0.03 mg/kg and control and P=0.08 between control and 0.1 mg/kg in individual t-
tests).
3.3. Effect of MOM Sal B on sucrose reinforcement
Figure 3 shows the effect of MOM Sal B (0.3 mg/kg) on responding maintained by sucrose
reinforcement. MOM Sal B significantly suppressed operant lever press responding for
sucrose reinforcements (P < 0.01).
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3.4. Effect of MOM Sal B on cocaine induced hyperactivity (cocaine self-administering and
drug naive rats)
The effect of MOM Sal B on cocaine produced hyperactivity in cocaine self-administering
and drug naive rats are presented Figures 4 and 5 respectively. No significant change in
cocaine produced hyperactivity (total activity) was observed following pre-treatment with
MOM Sal B in cocaine self-administering (P = 0.44; Fig. 4A) or drug naive rats (P = 0.24;
Fig. 5A). A further time course comparison also failed to show a significant effect of MOM
Sal B pre-treatment on cocaine induced hyperactivity in [F (11,108) = 1.38, P = 0.0.19; Fig.
4B] or drug naive rats [F (11,110) = 1.56, P = 0.24; Fig. 5B].
3.5. Effect of MOM Sal B on spontaneous open field activity
Figure 6 shows the effect of MOM Sal B (0.3 mg/kg) on spontaneous open field activity in
drug naïve rats. MOM Sal B had no significant effect on total ambulatory counts measured
over a 60 min time period (P = 0.22; Fig. 6A). A further time course analysis revealed no
significant effect of MOM Sal B treatment on spontaneous open field activity [F (1, 12) =
1.82, P = 0.20; Fig. 6B]. There was also no significant effect on total stereotypy counts or
stereotypy counts in bins of 5 min (P = 0.18; Fig. 6C and 6D).
3.6. Effect of MOM Sal B on depressive behavior (FST)
Figure 7 shows the effect of MOM Sal B (0.3 mg/kg) on depressive behavior in drug naïve
rats. MOM Sal B significantly decreased swimming time and increased immobility time (P
< 0.05) compared to vehicle. There was no significant change in climbing time.
4. Discussion
Results from the present study demonstrate that the longer acting and more potent Sal A
analogue, MOM Sal B, significantly attenuates cocaine-seeking in rats. The effect was not
due to a generalized impairment of motor function, since MOM Sal B at this dose failed to
alter either spontaneous open field activity or cocaine-produced hyperactivity, suggesting
that MOM Sal B has no measurable sedative effects at this dose. The effective dose of
MOM Sal B (0.3 mg/kg) also suppresses sucrose reinforced responding.
Previous studies with Sal A have shown that it is effective in attenuating cocaine prime
induced reinstatement of drug-seeking behavior (Morani et al., 2009) confirming its anti-
addiction effects when administered acutely. Studies have also shown Sal A has an
improved side effect profile compared to traditional κ opioid receptor agonists. However,
Sal A has a short duration of action, limiting its development as an anti-addiction agent.
Therefore, there is a need to investigate the pharmacological effects of longer acting Sal A
analogues on cocaine induced behaviors. Such studies have the potential to unearth novel
anti-cocaine agents. In vivo pharmacological studies have shown that MOM Sal B has a
longer duration of action compared to Sal A (Inan et al., 2009; Wang et al., 2008). MOM Sal
B is also more potent than Sal A at κ opioid receptors (Beguin et al., 2005; Munro et al.,
2008). Therefore, in this study we screened for pharmacological effects of MOM Sal B on
cocaine induced reinstatement in rats.
Our results indicate that an acute injection of MOM Sal B (0.3 mg/kg) significantly
attenuates cocaine-seeking behavior in rats (Fig. 2). The attenuation produced by MOM Sal
B and Sal A were seen at comparable doses (0.3 mg/kg; (Morani et al., 2009); current
study). However, MOM Sal B, at lower doses (0.03, 0.1 mg/kg), showed a non-significant
trend towards an increase in cocaine-seeking behavior (P = 0.2 and P = 0.08 respectively)
(Fig. 2). In another study, the arylacetamide κ opioid receptor agonist U50488H
significantly attenuated cocaine-induced drug seeking in rats (30 mg/kg) while a 10 fold
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lower dose of U50488H (3 mg/kg) showed a non-significant increase in cocaine-seeking
behavior (Morani et al., 2009). A recent study by Baker et al., (2009) showed that MOM Sal
B completely substituted for U50488H in discriminative stimulus tests in rats (Baker et al.,
2009). These effects produced by MOM Sal B were reversed by pre-treatment with κ opioid
receptor antagonist, nor-BNI, indicating a κ opioid receptor mediated effect. Additionally,
U50488H and MOM Sal B had comparable abilities to down-regulate the human κ opioid
receptor in vitro (Wang et al., 2008). Taken together, these data suggest a similarity in the
behavioral pharmacology effects produced by MOM Sal B and U50488H.
Since κ opioid receptor activation has been associated with disruptions in natural reward
related behaviors; we tested the effect of acute MOM Sal B exposure on oral sucrose
reinforcement in rats. A single injection of MOM Sal B at its effective dose (0.3 mg/kg)
significantly suppressed sucrose reinforcements (Fig. 3). Sal A on the other hand attenuated
cocaine-seeking without affecting sucrose reinforcement (Morani et al., 2009). These results
suggest that the ability to selectively attenuate cocaine-seeking behavior by novel
neoclerodane diterpene compounds may reflect their potency at κ opioid receptors; with
more potent κ opioid receptor agonists producing non-selective effects. This is the first
study to investigate the anti-addiction and side effect profile of novel Sal A analogues, we
do this utilising the preclinical gold-standard self-administration paradigm of cocaine prime-
induced relapse to model drug-seeking in humans. One study has investigated the anti-
addiction effects of the novel Sal A analogue β tetrahydropyran Sal B. This compound has
an ED50 in GTP-γS assays of 60 ±6 nM compared to 40 ±1 nM for Sal A and 6 ±1 nM for
Mom Sal B (Prevatt-Smith et al., 2011). However, no side effects were investigated for this
compound. The dose required for anti-addiction effects was 1 mg/kg compared to 0.3 mg/kg
for MOM Sal B. The potency and efficacy at κ opioid receptors are likely reasons for the
differences in dose required for observation of anti-addiction effects. Previous studies have
shown that U50488H suppressed responding to water reinforcement at doses which
attenuated cocaine self-administration (5, 10 mg/kg; (Glick et al., 1995)). These results
suggest a similar pharmacological effect profile of the more potent Sal A analogue MOM
Sal B with the traditional arylacetamide κ opioid receptor agonist U50488H.
In order to determine the effects of MOM Sal B on cocaine hyperactivity, we measured
cocaine induced locomotor activity in animals subjected to reinstatement tests (Fig. 4) and in
drug naive rats (Fig. 5). Data show a non-significant trend towards attenuation of cocaine
induced locomotor activity in both groups that was not significant when total ambulatory
counts were analysed over 60 min or at 5 min intervals using two-way ANOVA followed by
Bonferoni post-hoc tests. Spontaneous open field activity in drug naïve rats following MOM
Sal B (0.3 mg/kg) did not produce motor suppression in drug naive rats (Fig. 6), indicating
that MOM Sal B induced attenuation of cocaine-seeking observed in this study was not due
to motor suppression. Previous locomotion studies with MOM Sal B suggest that it
produced rapid, long lasting (approximately 3 h) immobility in mice which was dose
dependent and nor-BNI reversible (Wang et al., 2008). However, the same study also
showed that MOM Sal B increased locomotion in the Y-maze test in rats. We observed a
small but non-significant trend towards an increase in total ambulation counts in drug naïve
rats which were treated with MOM Sal B (0.3 mg/kg; Fig. 6). These findings indicate that
the effects of MOM Sal B on motor function might be species related (Wang et al., 2008;
current study).
Although Sal A has shown promising anti-cocaine effects, its poor pharmacokinetic profile
limits its clinical use. This study highlights that the longer acting, more potent Sal A
analogue, MOM Sal B, successfully produces anti-addiction behaviors without sedative
effects. However, MOM Sal B does suppress natural reward seeking behavior as shown by
sucrose reinforcement testing. A recent review by Wee and Koob (2010) highlights the
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unknown mechanism underlying the ability of the kappa system to modulate addiction and
the variability of its effects seen in the literature. While κ opioid receptor agonists have been
suggested to exert these effects by inducing aversive and punishment-like effects, this
requires further clarification (Wee and Koob, 2010). Recently, a study by Harden et al
(2012) showed that following chronic mild stress, Long-Evans rats given Sal A (1 mg/kg)
restored preference for a sucrose solution, suggesting antidepressant effects (Harden et al.,
2012). However in the FST model of depression, Sal A (0.3 mg/kg) in Sprague-Dawley rats
showed pro-depressive effects (Morani et al., 2012). Reasons underlying these differences
could be related to the choice of behavioural model used. The FST test applies the stressor at
the time of testing, whereas the chronic mild stress model applies the stressor prior to
testing. The latter model may in fact prove to be a better model to study stress in relation to
addiction behaviours. To our knowledge there have been no tests utilising this cronic mild
stress models with any Sal A analogue to date. Further studies will be needed to confirm if
this is the case for novel Sal A analogues. The present study adds to these recent findings by
suggesting that potent κ opioid receptor activation by MOM Sal B impairs natural reward
without sedation, whereas previously we showed Sal A does not impair natural reward or
cause sedative effects at the minimum effective anti-addiction dose of 0.3 mg/kg. Therefore
based on these current findings, we propose that ligands having Sal A like structures with
less potency for the κ opioid receptor and with affinities for other opioid receptors, might
produce anti-addiction effects with fewer undesirable side effects (Archer et al., 1996; Bart
et al., 2005; Kreek et al., 2005; Stevenson et al., 2004). Likewise, developing novel
neoclerodane diterpenes with less selectivity for κ opioid receptors over other opioid
receptors, may lead to a better tolerated side effect profile. Future studies testing this
hypothesis may identify effective anti-addiction pharmacotherapies with fewer side effects.
Although this study has shown that MOM Sal B has some undesirable side effects including
depression and modulation of natural reward. It is also the first to characterise both the anti-
addiction and side effect profile for a novel Sal A analogue. This study has demonstrated
that longer acting Sal A analogues have anti-addiction effects, a pharmacokinetic
improvement over both Sal A and also traditional κ opioid agonists. This information is
likely to guide further analogue development in future. It is clear that Sal A and analogues
have different binding and signalling properties compared to traditional κ opioid agonists
and warrant further investigation. Perhaps the development of “functional agonists” or
“mixed agonists” that can modulate κ opioid receptor signalling pathways differentially in
order to produce the desired anti-addiction effects with reduced side effects.
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Symbols indicate the number of active lever responses (±S.E.M..) produced during self-
administration (phase 1) and extinction (phase 2) of the reinstatement test. Responding was
high during phase 1 (102.9 ± 10.3). Once cocaine was replaced by saline, responding was
reduced by the end of phase 2 (11.3 ± 2.9). (n=7). One-way repeated measures ANOVA
followed by Bonferroni post-hoc tests were performed (*** P<0.001; **** P<0.0001).
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Active lever responses (+S.E.M.) produced during phase 3 of the reinstatement test are
shown. Rats which displayed extinguished lever pressing behaviour during the extinction
phase were treated with different doses of MOM Sal B (0, 0.03, 0.1 and 0.3 mg/kg) followed
by a priming injection of cocaine (20 mg/kg) and saline reinforced responses were recorded
for a period of 60 min. *P<0.05, data compared with vehicle treated group (0 mg/kg). One-
way ANOVA followed by Tukey post hoc test. n=5; treatment groups; n=6 ; control group.
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Mean lever responses (+S.E.M.) of a 10% oral sucrose solution following MOM Sal B (0,
0.3 mg/kg) treatment are shown. **P<0.01, data compared to 0 mg/kg. Student t-test. n=7.
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Cocaine induced locomotor activity in cocaine self-administering rats. Symbols represent
(A) total ambulatory counts (+S.E.M.) and (B) Locomotion at every 5 min interval during
the 60 min time period following 30 min habituation and vehicle or MOM Sal B (0, 0.3 mg/
kg) and cocaine (20 mg/kg) injections. Student t-test for total ambulation (P= 0.44) and
repeated measures two-way ANOVA followed by Bonferroni post-hoc test for 5 min
interval data. n=5-6) (P=0.07).
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Cocaine induced locomotor activity in drug naive rats. Symbols represent (A) total
ambulatory counts (+S.E.M.) and (B) Locomotion at every 5 min interval during the 60 min
time period following 30 min habituation and vehicle or MOM Sal B (0, 0.3 mg/kg) and
cocaine (20 mg/kg) injections. Student t-test for total ambulation and repeated measures
two-way ANOVA followed by Bonferroni post-hoc test for 5 min interval data. n=5-6
(P=0.24).
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Effects of MOM Sal B on locomotor activity in drug naive rats. Symbols represent (A) total
ambulatory counts (+S.E.M.) and (B) Locomotion at every 5 min interval during the 60 min
time period following MOM Sal B treatment and habituation. Total stereotypy counts (C)
and (D) at every 5 min time point are shown. Student t-test for total ambulation and
stereotypy counts and repeated measures two-way ANOVA followed by Bonferroni post-
hoc test for 5 min interval data. n=7.
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Symbols indicate mean lever press responses (+S.E.M.) of climbing, swimming and
immobility for 5 min following MOM Sal B (0, 0.3 mg/kg) treatment. *p<0.05, data
compared to 0 mg/kg. Student t-test. n=5 for each group.
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